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Eosinophilic colitis is a rare form of primary eosinophilic gastrointestinal disease that is poorly understood. Neonates and young
adults are more frequently aﬀected. Clinical presentation is highly variable depending on the depth of inﬂammatory response
(mucosal, transmural, or serosal). The pathophysiology of eosinophilic colitis is unclear but is suspected to be related to a
hypersensitivity reaction given its correlation with other atopic disorders and clinical response to corticosteroid therapy. Diagnosis
isthatofexclusionanddiﬀerentialdiagnosesaremanybecausecolonictissueeosinophiliamayoccurwithothercolitides(parasitic,
drug-induced, inﬂammatory bowel disease, and various connective tissue disorders). Similar to other eosinophilic gastrointestinal
disorders, steroid-based therapy and diet modiﬁcation achieve very good and durable responses. In this paper, we present our
experience with this rare pathology. Five patients (3 pediatric and 2 adults) presented with diarrhea and hematochezia. Mean age
at presentation was 26 years. Mean duration of symptoms before pathologic diagnosis was 8 months. Mean eosinophil count per
patient was 31 per high-power ﬁeld. The pediatric patients responded very well to dietary modiﬁcations, with no recurrences. The
adult patients were treated with steroids and did not respond. Overall mean followup was 22 (range, 2–48) months.
1.Introduction
Primaryeosinophilicgastrointestinaldisease(EGID)isarare
chronic inﬂammatory bowel condition of unknown etiology
that was originally described by Kaijser in 1937 [1]. EGID is
a spectrum of gastrointestinal (GI) disorders characterized
by inﬂammation rich in eosinophils without evidence of
otherknowncausesofeosinophilia(i.e.,parasitic,infectious,
drug reaction, or malignancy) [2]. The disease can aﬀect any
segment or combination of segments of the GI tract from
the esophagus to the rectum, giving rise to various clinical
presentations.
Eosinophilic colitis (EC) represents the least frequent
manifestation of EGID whether or not it eﬀects other
segments of the GI tract [3]. Since secondary eosinophilic
inﬂammation may occur in numerous GI disorders such as
IgE-mediated food allergy, gastroesophageal reﬂux disease,
and inﬂammatory bowel disease, the true incidence and
prevalence of primary EGID remains largely unknown. A
recently established world-wide-web registry found that this
disease mainly aﬀects the pediatric population, although it
has been reported in patients up to 68 years of age [3].
Most recently, eosinophilic esophagitis has been increasingly
recognized as a distinct condition that aﬀects about 1% of
the population, both in pediatric and adult populations [4].
2. Patients andMethods
We searched the computerized database of the Department
of Pathology at the University of Minnesota for all cases2 Gastroenterology Research and Practice
Table 1: Case series of four patients with eosinophilic colitis.
Patient Age gender Symptoms Relevant history Colon
involved
Location and
mean eosinophil
count per HPF
Treatment Outcome
1 2 months-M Hematochezia
Vesicoureteral
reﬂux with
hydronephrosis
Sigmoid Lamina
propria-23
Dietary
modiﬁcation
Resolution of
symptoms.
No
recurrence
2 4 months-M Hematochezia GERD, C. diﬀ
colitis. Ascending Lamina
propria-33
Dietary
modiﬁcation
Resolution of
symptoms.
No
recurrence
3 3 years-M Persistent
diarrhea
Selective IgA
deﬁciency Ascending
Lamina propria
and muscularis
mucosae-38
Dietary
modiﬁcation
Resolution of
symptoms.
No
recurrence
4 53 years-F Persistent
diarrhea
T-cell
lymphoma
(status after
BMT), C. diﬀ
colitis
Ascending &
rectum
Lamina propria
and muscularis
mucosae-29
Prednisone
Deceased
after 2
months
5 73 years-F Severe diarrhea
History of
rheumatoid
arthritis
Ascending
and
transverse
colon
Lamina propria
and muscularis
mucosae-32
Budesonide
Incomplete
response to
initial
treatment
HPF: high-power ﬁeld, GERD: gastroesophageal reﬂux disease, C. diﬀ: clostridium diﬃc i l e ,B M T :b o n em a r r o wt r a n s p l a n t .
of EC occurring between 2003 and 2010. Search criteria
speciﬁcally included the terms “eosinophilic colitis”, “colon
eosinophilia”, and “primary eosinophilic gastrointestinal
disease.”ThisstudywasapprovedbytheInstitutionalReview
Board of the University of Minnesota. A detailed review of
each patient’s medical chart was undertaken, concentrating
on demographics, presentation, diagnosis, therapy, and out-
come. Diagnostic criteria included a colonic biopsy showing
focal aggregates of eosinophils in the lamina propria, crypt
epithelium, and muscularis mucosa of at least 20 eosinophils
per high-power ﬁeld. Patients with evidence of secondary
systemic eosinophilia or tissue eosinophilia were excluded.
3.CaseSeries
A total of ﬁve patients (3 males, 3 pediatric, and 2 adults)
with a mean age of 26 years (range, 2 months to 73 years)
werediagnosedwithsymptomaticEC(Table1).Fivepatients
with secondary EC were excluded. The most common symp-
toms at presentation were diarrhea and hematochezia. The
mean duration of symptoms before pathologic diagnosis was
8(range,1–14)months.Onepediatricpatientalsohadselec-
tive IgA deﬁciency, but a pertinent workup for celiac sprue
was negative. The mean eosinophil count per patient was 31
per high-power ﬁeld, and eosinophil inﬁltration occurred in
the lamina propria in all patients, with three patients also
having muscularis mucosae inﬁltration. The most frequently
observed histologic alteration was neutrophilic cryptitis in
three patients (2 pediatric and 1 adult). The most common
site of colonic involvement was the ascending colon. Two
patients also had gastric involvement, and one patient had
involvement of the rectum. The most common endoscopic
ﬁndings included mucosal congestion and lymphonodular
hyperplasia. Three of the ﬁve patients were treated with
dietary modiﬁcations and had excellent responses with no
recurrence.Ofthetwoadultpatientstreatedwithoralsteroid
therapy, one had an incomplete response with only partial
improvement of symptoms, and the other patient died after
two months because of multiorgan failure. This last patient
had full-thickness involvement of the colon as well as T-
cell non-Hodgkin’s lymphoma involving mediastinal and
cervical lymph nodes. Pathologic evaluation on this patient
revealed negative mast cell immunoreactivity for CD25 and
hadnoevidencethatmalignancywasthecauseofsystemicor
tissue eosinophilia. The overall mean followup for the entire
group was 22 (range, 2–48) months.
4.Etiology
The etiology of primary EGID remains largely unknown.
Several studies have suggested a relationship with speciﬁc
food allergies. Approximately, 75% of aﬀected patients have
a history of allergy or atopy [2]. Cow’s milk and soy proteins
are the foods most frequently implicated in the infantile
form of EC, although the condition has been described in
infants exclusively breast fed or given protein hydrolyzed
formulas [2]. Even less is known about the potential causes
of the adult form of primary EC. A case report by Inamura
et al. [5] demonstrated the accumulation of mast cells in the
colon interstitium after immunohistochemical staining for
mast cell tryptase, which may suggest a possible pathogenic
role of IgE. Speciﬁc eosinophil chemoattractants, such asGastroenterology Research and Practice 3
interleukin-5 and eotaxins, may also have a pathogenic role
in EC [6]. Hahn and Hornick [7] speciﬁcally evaluated
mast cells in mucosal biopsies from patients with systemic
mastocytosis and a group of patients with diverse inﬂam-
matory disorders. They found that systemic mastocytosis
patients have signiﬁcantly higher densities of mast cells in
aggregates or sheets on GI mucosal biopsies and positive
immunoreactivity for CD25. These diagnostic criteria can be
helpful in excluding patients with secondary EC.
5. ClinicalPresentation
EC appears to have a bimodal distribution that aﬀects
neonates and young adults with no gender preference [2].
In general, EC has three hallmarks including peripheral
eosinophilia,segmentaleosinophilicinﬁltrationofthecolon,
and functional abnormalities.
Symptoms and signs of EC are usually nonspeciﬁc and,
depending on the aﬀected segment, include abdominal pain,
nausea, vomiting, diarrhea, bleeding, obstruction, weight
loss, and ascites. In 1970, Klein et al. [8] subdivided the
disease based on the layer of intestinal wall most extensively
inﬁltrated by eosinophils. This classiﬁcation provides good
correlation with the physical symptoms and the pathologic
ﬁndings. Mucosa-predominant disease results in diarrhea,
malabsorption and protein wasting [9]. Transmural disease
has been associated with bowel wall thickening on imaging
studies, obstruction, volvulus [9], intussusceptions [10,
11], and even perforation [12, 13]. Serosal involvement is
often distinguished by the presence of eosinophilic ascites
(Figure 1)[ 14].
6.Diagnosis
The diagnosis of EC is made from the presence of gastroin-
testinal symptoms, peripheral eosinophilia, endoscopic and
histological ﬁndings, and eosinophilic ascites, with no well-
deﬁned causes of eosinophilia on further evaluation. Twenty
to 90% of patients have an increase in the eosinophil count
in peripheral blood. Because some patients will not have this
ﬁnding, peripheral eosinophilia is not suﬃcient as an initial
screening tool. Radiological ﬁndings also depend on the
region and layer aﬀectedandmayshow strictures,thickening
of the bowel wall and mucosal folds [15], a rigid ileocecal
valve open to reﬂux, and ulcerative or polypoid lesions.
At colonoscopy, some patients have lymphonodular
hyperplasia while others have endoscopic features of mild
colitis including mucosal edema, patchy erythema, and loss
of vascularity (Figure 2). Changes can occur throughout the
colon but tend to be more prominent in the ascending colon
and rectum. The only clear diagnostic criteria for any of the
EGID entities pertain to eosinophilic esophagitis, which is
deﬁned by the presence of more than 15 eosinophils per
high-power ﬁeld in the esophageal squamous mucosa [16].
NosuchconsensusexistsforEC,althoughmostauthorshave
used a diagnostic threshold of 20 eosinophils per high-power
ﬁeld. Of note, normal values for tissue eosinophils vary
widelybetweendiﬀerentsegmentsofthecolon,rangingfrom
R
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Figure 1: Computed tomography of the abdomen and pelvis
showing colonic wall thickening and ascites in patient 4 with full-
thickness eosinophilic colitis.
Figure 2: Colonoscopic view of a patient with eosinophilic
colitis showing mild inﬂammatory changes, mucosal edema, patchy
erythema, and loss of vascularity.
<10 eosinophils per high-power ﬁeld in the rectum to >30 in
the cecum [17], thus, location of colonic biopsy is critically
important for proper interpretation of ﬁndings. Histological
features include focal aggregates of eosinophils in the lamina
propria, crypt epithelium and muscularis mucosa (Figure 3).
Tissue eosinophilia in the colon may result from a
number of conditions (Table 2), and EC remains a diagnosis
of exclusion. Colonoscopic biopsies obtained from patients
with inﬂammatory bowel disease, particularly with Crohn’s
colitis, often show severe tissue eosinophilia [18]. Parasitic
infection of the colon may lead to marked eosinophilic
inﬁltration, and repeated stool or serological testing may
be needed to conﬁrm this speciﬁc etiology. Drug-induced4 Gastroenterology Research and Practice
Table 2: Diﬀerential diagnoses of eosinophilic colitis.
Inﬂammatory bowel disease
Drug-induced colitis
Clozapine
Carbamazepine
Rifampicin
Gold
NSAID’s
Tacrolimus
Parasitic colitis
Enterobius vermicularis
Strongyloides stercoralis
Trichuris trichiura
Hypereosinophilic syndrome
Systemic mastocytosis
Allogeneic bone marrow transplantation
Tolosa-Hunt syndrome
NSAID: nonsteroidal antiinﬂammatory drug.
Figure 3: Microscopic view of the colon wall demonstrating tissue
eosinophilia.
EC has also been described in response to several med-
ications, including clozapine, carbamazepine, rifampicin,
nonsteroidal antiinﬂammatory agents, tacrolimus, and gold
[19–25]. Other conditions associated with EC include sys-
temic mastocytosis, malignancy, autoimmune connective
tissue disease including scleroderma, dermatomyositis and
polymyositis, [9, 26, 27]a l l o g e n e i cb o n em a r r o wt r a n s -
plantation [28], and the rare Tolosa-Hunt syndrome that
features inﬂammatory ophthalmoparesis [29]. Idiopathic
hypereosinophilic syndrome may also aﬀect the colon, but
this rare condition presents with sustained and marked
peripheral eosinophilia with end-organ damage that extends
beyond the gastrointestinal tract (e.g., heart and skin) [30].
7. Treatment
Currently, there is no level I evidence to guide treatment
of EC. Therapies for EGID have been based mainly on
case reports and small case series. The beneﬁcial eﬀect
of withdrawing oﬀending dietary triggers and prescribing
elemental diets have been limited to cases with speciﬁc
food allergies, especially in treating neonatal disease [31]. In
contrast, the response of adults to dietary modiﬁcation is less
clear, and those with more severe symptoms receive some
sort of pharmacologic therapy.
Allergy testing can aid in the identiﬁcation of speciﬁc
antigens and the development of an elimination diet.
However, allergy testing has low sensitivity and speciﬁcity
with high false-positive rates and should be interpreted
with caution. In a study of 35 patients with eosinophilic
esophagitis who were placed on an empiric elimination diet
for a 6-week trial, 74% showed improvement on esophageal
biopsy [32].
Corticosteroids are the mainstay for initial management
andhaveproventobeeﬀectiveforsymptomcontrolinEC[2,
33, 34]. The majority of cases will respond within 2 weeks of
treatment.Relapseisfrequentandrequiresrecurrentcourses,
which can lead to steroid dependence. Several studies have
evaluated the eﬃcacy of steroids in the various types of
EGID and have shown signiﬁcant improvement in symptom
management. However, no histologic correlation has been
demonstrated in EC. Also, the optimal duration of corticos-
teroid therapy has not yet been established. Often, a dosing
strategy similar to that used in inﬂammatory bowel disease
hasbeenutilized.Budesonide,asyntheticoralcorticosteroid,
has shown to be eﬀective in EC, particularly when the right
colon and ileum are aﬀected [35]. In a randomized, double-
blind, placebo-controlled trial, Straumann et al. [36] showed
that a 15-day regimen of oral budesonide was highly eﬀective
in inducing a histologic and clinical remission in adolescent
and adult patients with active eosinophilic esophagitis. Oral
viscous budesonide has also been found to be an eﬀective
treatment of eosinophilic esophagitis in children, improving
symptoms and both endoscopic and histologic features [37].
Topical corticosteroid treatment (inhaled ﬂuticasone) has
been used in patients with eosinophilic esophagitis and has
shown to be eﬀective in symptom control but with frequent
recurrences after treatment discontinuation [38, 39]. It must
be emphasized that eﬀorts to rule out parasitic or drug-
induced EC are important since empiric treatment with
corticosteroids may worsen the patient’s condition.
Immunomodulating therapies may provide an alterna-
tive to corticosteroids for chronic maintenance therapy.
These include mast cell inhibitors, antihistamines, leuko-
trienereceptorantagonists,andnewerbiologicimmunother-
apies. Ketotifen, an H1 antihistamine, has been shown
to decrease symptoms as well as tissue eosinophilia in
EGID [40, 41]. The leukotriene inhibitor montelukast, an
agent that blocks the action of eosinophil chemoattractant
leukotriene D4, appears also to have eﬃcacy [42, 43]. Mast
cell stabilizers, such as cromolyn, are eﬀective by inhibiting
the release of mast cell mediators such as histamine, platelet
activating factor, and leukotoxin [44]. More recently, the
role of immunotherapy has also been studied, with favorable
outcomesreportedbyusingmonoclonalantibodiestargeting
interleukin 5 (mepolizumab) and IgE (omalizumab) [45,
46].
Currently, the only level I evidence for EGID treat-
ment is for eosinophilic duodenitis. In a double-blinded,
randomized, and controlled study evaluating the eﬃcacy
of montelukast in 40 children and adolescents, FriesenGastroenterology Research and Practice 5
et al. [47] showed signiﬁcant symptom improvement in the
montelukast arm (62%) versus the placebo arm (32%) [48].
Ofimportance,moststudiesevaluatingpharmacologictreat-
ment of EC are largely observational, and medications were
evaluated in combination with other treatment modalities
such as dietary modiﬁcations.
Operative treatment is only indicated for the compli-
cations of EC. These include obstruction, volvulus, intus-
susception and perforation. Segmental anatomic colonic
resection is recommended with no clear consensus or
evidence to support primary anastomosis or diversion. One
must consider the degree of peritoneal contamination and
overall physiologic status of the patient, as with other
indications for colonic surgery. Of importance, eosinophilic
ascites in the presence of colitis may be misdiagnosed as a
free perforation. Depending on the patient’s overall status,
a diagnostic paracentesis or diagnostic peritoneal lavage
may be considered initially to conﬁrm the diagnosis and
potentially avoid major surgery in an immunocompromised
patient.
8. Conclusions
EC is a rare manifestation of EGID without a primary
etiologyfortissuehypereosinophilia.Thepathophysiologyof
this condition is not well understood, but a hypersensitivity
mechanism is suspected given its increased association with
other atopic conditions and clinical improvement with
corticosteroids. In contrast to increased trends seen in
esophageal disease, the prevalence of EC does not appear to
be increasing. This may suggest a diﬀerent pathophysiology
for EC. Symptoms are non-speciﬁc and correlate with the
degree of eosinophilic inﬁltration of the colonic wall. The
deﬁnitive diagnosis of EC is made with endoscopic biopsy
demonstrating colonic tissue hypereosinophilia and the
absence of any primary disorders that may cause secondary
eosinophilic inﬁltrates. No clear consensus exists with
regards to the degree of tissue eosinophilia or the presence of
distinct pathologic ﬁndings. While the pediatric form of EC
often subsides without intervention or after the withdrawal
of atopic stimuli, the adult form may relapse and require
short-term or repeated courses of steroid therapy. EC is
primarilyadiagnosisofexclusionbutneedstobeincludedin
the diﬀerential diagnosis of many GI conditions that present
with non-speciﬁc symptoms and eosinophilia. Additional
studies are needed to further delineate the pathophysiology
of EGID and to determine optimal treatment regimens for
EC.
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